NeoGenomics, Inc. (NASDAQ:NEO) Receives Average Rating of "Hold" from Analysts

NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) has received a consensus rating of "Hold" from the eleven brokerages that are covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $13.83.

Several brokerages recently issued reports on NEO. Leerink Partners cut shares of NeoGenomics from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $25.00 to $9.00 in a research report on Wednesday, April 30th. Wall Street Zen upgraded shares of NeoGenomics from a "sell" rating to a "hold" rating in a report on Tuesday, May 13th. The Goldman Sachs Group cut their price target on NeoGenomics from $15.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Morgan Stanley cut their price target on NeoGenomics from $17.00 to $10.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 1st. Finally, Needham & Company LLC cut their price target on NeoGenomics from $18.00 to $8.50 and set a "buy" rating on the stock in a research note on Tuesday, April 29th.

NeoGenomics Trading Up 0.7%

Shares of NASDAQ NEO traded up $0.05 during midday trading on Wednesday, reaching $7.00. The company had a trading volume of 2,345,929 shares, compared to its average volume of 1,245,273. NeoGenomics has a one year low of $6.08 and a one year high of $19.12. The company has a quick ratio of 1.95, a current ratio of 2.05 and a debt-to-equity ratio of 0.38. The firm's fifty day moving average price is $8.01 and its 200-day moving average price is $11.39. The stock has a market cap of $900.90 million, a PE ratio of -11.48 and a beta of 1.65.

NeoGenomics (NASDAQ:NEO - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The medical research company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.06). NeoGenomics had a negative return on equity of 2.21% and a negative net margin of 11.54%. The company had revenue of $168.04 million during the quarter, compared to analysts' expectations of $171.38 million. During the same period last year, the firm earned ($0.02) earnings per share. NeoGenomics's revenue for the quarter was up 7.6% on a year-over-year basis. On average, equities research analysts anticipate that NeoGenomics will post -0.2 earnings per share for the current year.

Insider Activity at NeoGenomics

In other news, CEO Anthony P. Zook bought 18,900 shares of the company's stock in a transaction on Tuesday, May 6th. The shares were acquired at an average cost of $7.88 per share, with a total value of $148,932.00. Following the completion of the transaction, the chief executive officer now owns 18,900 shares of the company's stock, valued at approximately $148,932. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director David Brian Perez acquired 10,000 shares of the company's stock in a transaction that occurred on Monday, May 5th. The stock was acquired at an average cost of $7.63 per share, for a total transaction of $76,300.00. Following the acquisition, the director now owns 10,000 shares of the company's stock, valued at $76,300. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 70,600 shares of company stock worth $550,438 over the last quarter. Company insiders own 2.40% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Swiss National Bank lifted its stake in NeoGenomics by 1.0% in the 4th quarter. Swiss National Bank now owns 252,100 shares of the medical research company's stock worth $4,155,000 after purchasing an additional 2,600 shares in the last quarter. Rhumbline Advisers raised its stake in NeoGenomics by 2.4% during the fourth quarter. Rhumbline Advisers now owns 389,003 shares of the medical research company's stock valued at $6,411,000 after purchasing an additional 9,098 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of NeoGenomics by 2.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,161,352 shares of the medical research company's stock valued at $19,139,000 after buying an additional 26,701 shares in the last quarter. GAMMA Investing LLC raised its position in shares of NeoGenomics by 1,107.7% during the 1st quarter. GAMMA Investing LLC now owns 17,765 shares of the medical research company's stock valued at $1,872,000 after buying an additional 16,294 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of NeoGenomics during the 4th quarter valued at about $453,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.